Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
- U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- - European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired hypothalamic obesity -
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Eli Lilly ( NYSE:LLY )
Novo's pill requires ~75 times more active ingredient per week than Wegovy injections. Lilly has $808.5 million in orforglipron inventory ahead of its planned 2026 launch. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Rhythm ( RYTM ) Q2 Revenue Jumps 67%
Rhythm Pharmaceuticals ( NASDAQ:RYTM ) , a biopharmaceutical company focused on rare genetic diseases related to obesity, reported its Q2 2025 earnings on August 5, 2025. However, the company reported a GAAP net loss per share of ( $0.75 ) .
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences ( EXAS ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Rhythm Pharmaceuticals, Inc. ( RYTM ) Q2 Earnings Expected to Decline
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in This Under-the-Radar Weight Loss Stock?
If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk. That's not a bad strategy since these two are the undisputed leaders in the field.
Rhythm Pharmaceuticals CFO Sells 42,120 Shares
Smith Hunter C, Chief Financial Officer of Rhythm Pharmaceuticals ( NASDAQ:RYTM ) , reported mixed transactions totaling 42,120 shares on July 9, 2025, as disclosed in an SEC Form 4 filing, resulting in post-transaction holdings of 116,915 shares.How do the post-transaction holdings position the ...
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity - - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s -
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO ...
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity ...
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
Rhythm Pharmaceuticals ( RYTM ) Stock Jumps 36.6%: Will It Continue to Soar?
Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
Rhythm announced pricing of its upsized public offering of 2,058,824 shares of common stock at a price of $85.00 per share.
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
BOSTON, July 09, 2025 ( GLOBE NEWSWIRE ) -- Rhythm Pharmaceuticals, Inc. ( Nasdaq: RYTM ) ( "Rhythm" ) , a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of ...
Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
Bivamelagon reduced BMI by 9.3% at 600mg vs. 2.2% BMI increase on placebo in acquired hypothalamic obesity patients. Hunger scores dropped by over 2.8 points in high-dose groups vs. a 0.8-point increase in the placebo group. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - First Majestic Silver ( NYSE:AG ) , AES ( NYSE:AES )
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Verona Pharma plc VRNA rose sharply during Wednesday's session after Merck announced it will acquire the company in a $10 billion deal.
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reductions in bivamelagon trial were consistent with BMI reductions achieved by setmelanotide in past ...
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
BOSTON, June 25, 2025 ( GLOBE NEWSWIRE ) -- Rhythm Pharmaceuticals, Inc. ( Nasdaq: RYTM ) , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that three late-breaking abstracts have been ...
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
BOSTON, June 25, 2025 ( GLOBE NEWSWIRE ) -- Rhythm Pharmaceuticals, Inc.
Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
Rhythm Pharmaceuticals RYTM has outperformed the market over the past 5 years by 12.84% on an annualized basis producing an average annual return of 25.91%. Currently, Rhythm Pharmaceuticals has a market capitalization of $4.21 billion.
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity ( N=35 ) Treated with Setmelanotide for up to Nine Months in French Early-access Program - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology ( ESPE-ESE ).
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q1 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -17.39% and 18.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Wave Life Sciences ( WVE ) to Report a Decline in Earnings: What to Look Out for
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Rhythm Pharmaceuticals, Inc. ( RYTM ) Report Negative Earnings Next Week? What You Should Know
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals ( RYTM ) Moves 5.2% Higher: Will This Strength Last?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008
Nasdaq witnesses its largest intraday comeback since Oct. 10, 2008. We highlight five stocks at the forefront of the rebound.
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday - Apple ( NASDAQ:AAPL ) , Applied Optoelectronics ( NASDAQ:AAOI )
U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday. Shares of Marvell Technology, Inc. MRVL rose sharply during Tuesday's session after Infineon Technologies agreed to acquire its Automotive Ethernet Business for $2.5 billion in cash.
Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Autodesk ( NASDAQ:ADSK ) , Centene ( NYSE:CNC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer cut Autodesk, Inc. ADSK price target from $350 to $300.
Rhythm Pharmaceuticals ( RYTM ) Surges 17.1%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
80% of patients on setmelanotide saw ≥5% BMI reduction after 52 weeks, versus a 3.3% BMI increase on placebo. Setmelanotide cut BMI by 19.2% in adults and 20.2% in patients under 18 compared to placebo. With stocks plunging, steady income is key.
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy ...
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer - Zenas BioPharma ( NASDAQ:ZBIO )
WALTHAM, Mass., April 07, 2025 ( GLOBE NEWSWIRE ) -- Zenas BioPharma, Inc. ( "Zenas" or the "Company" ) ZBIO, a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the ...
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients ( N=120 ) with Acquired Hypothalamic Obesity
-- Patients with acquired hypothalamic obesity on setmelanotide therapy ( n=81 ) achieved mean BMI change of -16.5% compared with +3.3% for placebo ( n=39 ) at 52 weeks ( p<0.0001 ) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older ( n=49 ) at 52 weeks ...
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Company to host conference call on April 7 at 8 a.m. ET Company to host conference call on April 7 at 8 a.m. ET ...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
BOSTON, March 19, 2025 ( GLOBE NEWSWIRE ) -- Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
New registry study to focus on impact of fatigue in people with craniopharyngioma New registry study to focus on impact of fatigue in people with craniopharyngioma ...
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q4 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -4.35% and 2.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics ( CYTK ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina Healthcare to Report Q4 Earnings: What Do the Estimates Say?
MOH's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Can Centene's Q4 Earnings Navigate Through Rising Medical Costs?
CNC's fourth-quarter earnings are likely to have benefited from growing Commercial business.
Rising Medical Costs to Affect Cigna Q4 Earnings? Check Estimates Here
CI's fourth-quarter results are likely to have benefited from growing premiums and pharmacy revenues.
Wall Street Analysts Think Rhythm Pharmaceuticals ( RYTM ) Could Surge 26.36%: Read This Before Placing a Bet
The consensus price target hints at a 26.4% upside potential for Rhythm Pharmaceuticals (RYTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Rhythm Pharmaceuticals ( RYTM ) Soars 5.5%: Is Further Upside Left in the Stock?
Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
-- Preliminary unaudited net revenues from global sales of IMCIVREE® ( setmelanotide ) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in ...
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. RYTM, a developer of treatment for rare obesity disorders. The pharmaceutical industry's focus on weight management is drawing strong investor interest, with Rhythm Pharmaceuticals standing out for targeting rare obesity disorders that ...
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® ( setmelanotide ) for Patients as Young as 2 Years Old
BOSTON, Dec. 20, 2024 ( GLOBE NEWSWIRE ) -- Rhythm Pharmaceuticals, Inc. ( Nasdaq: RYTM ) , a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S.
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® ( setmelanotide ) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
BOSTON, Dec. 03, 2024 ( GLOBE NEWSWIRE ) -- Rhythm Pharmaceuticals, Inc. ( Nasdaq: RYTM ) , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom's Medicines & Healthcare ...
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® ( setmelanotide ) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet...
Rhythm Pharmaceuticals Announces â-¼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet...
